{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:32:00Z","timestamp":1790627520136,"version":"4.1.0"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Lung Cancer Research Foundation-Pfizer"},{"name":"Guardant Health and Biomark inc"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.critrevonc.2020.102978","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T22:28:46Z","timestamp":1588631326000},"page":"102978","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"special_numbering":"C","title":["Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)"],"prefix":"10.1016","volume":"151","author":[{"given":"Christian","family":"Rolfo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s F.","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Cristofanilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jose","family":"Diaz Mochon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8571-7163","authenticated-orcid":false,"given":"Ignacio","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Raez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-1972","authenticated-orcid":false,"given":"Alessandro","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Lorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Malapelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Gil-Bazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloisa","family":"Jantus-Lewintre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Pauwels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2020.102978_bib0005","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0010","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-018-0058-3","article-title":"Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection","volume":"15","author":"Abbosh","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0015","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2018.4305","article-title":"Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer","volume":"5","author":"Aggarwal","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0020","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jtho.2019.11.024","article-title":"Circulating tumor DNA analysis for patients with oncogene-addicted NSCLC with isolated central nervous system progression","volume":"15","author":"Aldea","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0025","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-18-1127","article-title":"Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer","volume":"79","author":"Anagnostou","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0030","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andre","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0035","article-title":"A panel of noncoding RNAs in non-small-cell lung cancer","author":"Bagheri","year":"2018","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0040","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/annonc\/mdw619","article-title":"Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine","volume":"28","author":"Batth","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0045","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.1016\/S1470-2045(17)30373-X","article-title":"Genomic approaches to accelerate cancer interception","volume":"18","author":"Beane","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0050","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1158\/1078-0432.CCR-13-2933","article-title":"Detection of cancer DNA in plasma of patients with early-stage breast cancer","volume":"20","author":"Beaver","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0055","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-19-0225","article-title":"High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden","volume":"25","author":"Benayed","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0060","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0065","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8030414","article-title":"Are there new biomarkers in tissue and liquid biopsies for the early detection of non-small cell lung cancer?","volume":"8","author":"Calabrese","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0070","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0075","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1158\/1078-0432.CCR-13-3063","article-title":"Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST\/IFCT-1002","volume":"20","author":"Couraud","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0080","article-title":"Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial","author":"Cremolini","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0085","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/jama.2010.292","article-title":"Circulating tumor cells revisited","volume":"303","author":"Cristofanilli","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0090","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3389\/fgene.2019.00390","article-title":"Circular RNAs and RNA splice variants as biomarkers for prognosis and therapeutic response in the liquid biopsies of lung cancer patients","volume":"10","author":"de Fraipont","year":"2019","journal-title":"Front. Genet."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0095","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00428-019-02571-3","article-title":"IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing","volume":"474","author":"Deans","year":"2019","journal-title":"Virchows Arch."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12967-018-1624-2","article-title":"Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients","volume":"16","author":"Delgado-Urena","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0105","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2174\/1389201018666170224105600","article-title":"Clinical applications of personalized medicine: a new paradigm and challenge","volume":"18","author":"Di Sanzo","year":"2017","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0110","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0115","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0120","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.csbj.2018.10.002","article-title":"Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management","volume":"16","author":"Elazezy","year":"2018","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0125","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3322\/caac.21560","article-title":"The current state of molecular testing in the treatment of patients with solid tumors, 2019","volume":"69","author":"El-Deiry","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-017-0564-y","article-title":"The emerging role of \u201cLiquid biopsies,\u201d circulating tumor cells, and circulating cell-free tumor DNA in lung cancer diagnosis and identification of resistance mutations","volume":"19","author":"Esposito","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0135","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003726","article-title":"Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA","volume":"4","author":"Forshew","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0140","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1373\/clinchem.2015.242453","article-title":"Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies","volume":"61","author":"Freidin","year":"2015","journal-title":"Clin. Chem."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0145","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","article-title":"Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer","volume":"34","author":"Fribbens","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0150","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz394.079","article-title":"LBA81_PRPhase II\/III blood first assay screening trial (BFAST) in patients (pts) with treatment-na\u00efve NSCLC: initial results from the ALK+ cohort","volume":"30","author":"Gadgeel","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0155","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","volume":"24","author":"Gandara","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0160","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.1838","article-title":"Assessment of molecular relapse detection in early-stage breast Cancer","author":"Garcia-Murillas","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0165","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0170","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1158\/1078-0432.CCR-17-3044","article-title":"New insights from studies of clonal hematopoiesis","volume":"24","author":"Gibson","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0175","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1755-0998.2011.03024.x","article-title":"Field guide to next-generation DNA sequencers","volume":"11","author":"Glenn","year":"2011","journal-title":"Mol. Ecol. Resour."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0180","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41391-018-0076-3","article-title":"Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study","volume":"22","author":"Govers","year":"2019","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0185","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz139","article-title":"Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy","author":"Hamfjord","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0190","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1039\/c2cp43859c","article-title":"Recent developments and future directions in SERS for bioanalysis","volume":"15","author":"Harper","year":"2013","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0195","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fmed.2018.00009","article-title":"Liquid biopsy in clinical management of breast, lung, and colorectal Cancer","volume":"5","author":"Hench","year":"2018","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.conctc.2018.08.009","article-title":"Master protocol trials in oncology: review and new trial designs","volume":"12","author":"Hirakawa","year":"2018","journal-title":"Contemp. Clin. Trials Commun."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0205","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1158\/1078-0432.CCR-18-0143","article-title":"False-positive plasma genotyping due to clonal hematopoiesis","volume":"24","author":"Hu","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0210","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0215","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jtho.2017.04.003","article-title":"Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non-small cell lung Cancer","volume":"12","author":"Jenkins","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0220","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/nprot.2014.170","article-title":"Detecting ultralow-frequency mutations by duplex sequencing","volume":"9","author":"Kennedy","year":"2014","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0225","doi-asserted-by":"crossref","first-page":"9530","DOI":"10.1073\/pnas.1105422108","article-title":"Detection and quantification of rare mutations with massively parallel sequencing","volume":"108","author":"Kinde","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0230","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1373\/clinchem.2008.121962","article-title":"PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment","volume":"55","author":"Kristensen","year":"2009","journal-title":"Clin. Chem."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0235","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/annonc\/mdx765","article-title":"Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma","volume":"29","author":"Krug","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0240","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40291-017-0259-y","article-title":"Epi proColon((R)) 2.0 CE: a blood-based screening test for colorectal cancer","volume":"21","author":"Lamb","year":"2017","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0245","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Le Tourneau","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0250","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","article-title":"Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer","volume":"25","author":"Leighl","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0255","doi-asserted-by":"crossref","first-page":"13111","DOI":"10.1007\/s13277-016-5190-z","article-title":"Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencing","volume":"37","author":"Li","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0260","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/annonc\/mdz046","article-title":"Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium","volume":"30","author":"Li","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0265","doi-asserted-by":"crossref","first-page":"26625","DOI":"10.18632\/oncotarget.15775","article-title":"Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0270","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jtho.2017.12.001","volume":"13","author":"Lindeman","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0275","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/annonc\/mdy513","article-title":"Biological background of the genomic variations of cf-DNA in healthy individuals","volume":"30","author":"Liu","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0280","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/14737159.2017.1288568","article-title":"Profile of the Roche cobas(R) EGFR mutation test v2 for non-small cell lung cancer","volume":"17","author":"Malapelle","year":"2017","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0285","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-4939-8973-7_2","article-title":"Cell-free DNA: an overview of sample types and isolation procedures","volume":"1909","author":"Martignano","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0290","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0295","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0300","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1586\/14737159.2015.975212","article-title":"Plasma methylated septin 9: a colorectal cancer screening marker","volume":"15","author":"Molnar","year":"2015","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0305","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nrclinonc.2017.186","article-title":"The evidence framework for precision cancer medicine","volume":"15","author":"Moscow","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0310","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jmoldx.2015.08.001","article-title":"Ultrasensitive detection of multiplexed somatic mutations using MALDI-TOF mass spectrometry","volume":"18","author":"Mosko","year":"2016","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0315","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1158\/0008-5472.CAN-11-4037","article-title":"Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing","volume":"72","author":"Narayan","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0320","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.csbj.2018.05.002","article-title":"ctDNA and CTCs in liquid biopsy - current status and where we need to progress","volume":"16","author":"Neumann","year":"2018","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0325","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0330","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2018.07.007","article-title":"The liquid biopsy in the management of colorectal cancer patients: current applications and future scenarios","volume":"70","author":"Normanno","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0340","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41467-018-03215-x","article-title":"Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer","volume":"9","author":"O\u2019Leary","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0345","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-13-2482","article-title":"Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA","volume":"20","author":"Oxnard","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0350","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1200\/JCO.2016.66.7162","article-title":"Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-Cell lung Cancer","volume":"34","author":"Oxnard","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0355","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2174\/1568009618666180308125110","article-title":"Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis","volume":"18","author":"Passiglia","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0360","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/1078-0432.CCR-15-1627-T","article-title":"Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung Cancer patients","volume":"22","author":"Paweletz","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00356","article-title":"Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non\u2013small-cell lung cancer using a decision analytic model","author":"Pennell","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0370","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1158\/0008-5472.CAN-18-1082","article-title":"Early noninvasive detection of response to targeted therapy in non-small cell lung cancer","volume":"79","author":"Phallen","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0375","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/gim.2013.122","article-title":"The economic value of personalized medicine tests: what we know and what we need to know","volume":"16","author":"Phillips","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0380","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13148-017-0351-5","article-title":"Circulating nucleosomes as new blood-based biomarkers for detection of colorectal cancer","volume":"9","author":"Rahier","year":"2017","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0385","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/PPO.0000000000000308","article-title":"Future of liquid biopsies with growing technological and bioinformatics studies: opportunities and challenges in discovering tumor heterogeneity with single-cell level analysis","volume":"24","author":"Ramalingam","year":"2018","journal-title":"Cancer J."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180809","article-title":"Hypermethylated DNA, a circulating biomarker for colorectal cancer detection","volume":"12","author":"Rasmussen","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0395","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer","author":"Reinert","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0400","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.0237","article-title":"Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial","author":"Rizvi","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0405","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","article-title":"Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial","volume":"25","author":"Rodon","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0410","first-page":"539","article-title":"Liquid biopsies in lung cancer: the new ambrosia of researchers","volume":"1846","author":"Rolfo","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0415","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jtho.2018.05.030","article-title":"Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC","volume":"13","author":"Rolfo","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0420","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000398","article-title":"Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer","volume":"3","author":"Rolfo","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0425","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41591-019-0380-z","article-title":"Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study","volume":"25","author":"Rothwell","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0430","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/jamaoncol.2016.0173","article-title":"Prospective validation of rapid plasma genotyping for the detection of egfr and kras mutations in advanced lung cancer","volume":"2","author":"Sacher","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0435","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1196\/annals.1448.025","article-title":"Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer","volume":"1137","author":"Schwarzenbach","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0440","doi-asserted-by":"crossref","DOI":"10.1590\/0102-311x00014317","article-title":"Welfarism and extra-welfarism: a critical overview","volume":"33","author":"Seixas","year":"2017","journal-title":"Cad. Saude Publica"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0445","doi-asserted-by":"crossref","first-page":"18485","DOI":"10.18632\/oncotarget.7608","article-title":"Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer","volume":"7","author":"Shan","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0450","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.9027","article-title":"Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial","volume":"36","author":"Shepherd","year":"2018","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0455","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2017-07-746453","article-title":"Age-related clonal hematopoiesis","volume":"131","author":"Shlush","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0460","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/JTO.0000000000000516","article-title":"Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung Cancer mutation consortium experience","volume":"10","author":"Sholl","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0465","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0470","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/jama.2019.3241","article-title":"Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database","volume":"321","author":"Singal","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0475","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.lungcan.2016.04.026","article-title":"Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients","volume":"107","author":"Sorber","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0480","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10090290","article-title":"A multicenter study to assess EGFR mutational status in plasma: focus on an optimized workflow for liquid biopsy in a clinical setting","volume":"10","author":"Sorber","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0485","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11040458","article-title":"Circulating cell-free DNA and RNA analysis as liquid biopsy: optimal centrifugation protocol","volume":"11","author":"Sorber","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0490","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1634\/theoncologist.2016-0178","article-title":"Cell-free DNA in metastatic colorectal Cancer: a systematic review and meta-analysis","volume":"22","author":"Spindler","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0495","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00191","article-title":"Orthogonal comparison of four plasma NGS tests with tumor suggests technical factors are a major source of assay discordance","author":"Stetson","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0505","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2019.06.004","article-title":"Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA","volume":"134","author":"Supplee","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0510","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S1470-2045(15)00138-2","article-title":"Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0515","doi-asserted-by":"crossref","first-page":"52142","DOI":"10.18632\/oncotarget.18479","article-title":"Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients","volume":"8","author":"Takeshita","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0520","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2019.11.022","article-title":"Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis","volume":"139","author":"Tan","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0525","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9018","article-title":"Complete clearance of plasma EGFR mutations as a predictor of outcome on osimertinib in the AURA trial","volume":"35","author":"Thress","year":"2017","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0530","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA2553","article-title":"Precision medicine: clinical outcomes including long-term survival according to the pathway targeted and treatment period\u2013the IMPACT study","volume":"36","author":"Tsimberidou","year":"2018","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0535","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1373\/clinchem.2015.241414","article-title":"Diagnostic accuracy of noninvasive genotyping of EGFR in lung Cancer patients by deep sequencing of plasma cell-free DNA","volume":"61","author":"Uchida","year":"2015","journal-title":"Clin. Chem."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0540","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1097\/JTO.0000000000000282","article-title":"A new biomarker panel in bronchoalveolar lavage for an improved lung cancer diagnosis","volume":"9","author":"Uribarri","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0545","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/1878-0261.12037","article-title":"Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions","volume":"11","author":"van Dessel","year":"2017","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0550","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/cam4.1184","article-title":"Preanalytical blood sample workup for cell-free DNA analysis using Droplet Digital PCR for future molecular cancer diagnostics","volume":"6","author":"van Ginkel","year":"2017","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0555","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s11684-017-0526-7","article-title":"Application of liquid biopsy in precision medicine: opportunities and challenges","volume":"11","author":"Wang","year":"2017","journal-title":"Front. Med."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0560","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cancergen.2018.02.004","article-title":"Comparison of 4 commercial kits for the extraction of circulating DNA from plasma","volume":"228\u2013229","author":"Warton","year":"2018","journal-title":"Cancer Genet."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0565","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.7150\/thno.15871","article-title":"Simple, sensitive and accurate multiplex detection of clinically important melanoma DNA mutations in circulating tumour DNA with SERS nanotags","volume":"6","author":"Wee","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0570","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.lungcan.2009.11.009","article-title":"Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis","volume":"69","author":"Zhang","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0575","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.canlet.2010.12.011","article-title":"Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer","volume":"303","author":"Zhang","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2020.102978_bib0580","article-title":"Circulating cell free DNA as the diagnostic marker for ovarian Cancer: a systematic review and meta-analysis","volume":"11","author":"Zhou","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2020.102978_bib0585","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.9020","article-title":"Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial","volume":"37","author":"Zhou","year":"2019","journal-title":"JCO"}],"updated-by":[{"DOI":"10.1016\/j.critrevonc.2020.103058","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000}}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820301165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820301165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T03:20:23Z","timestamp":1722828023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842820301165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":117,"alternative-id":["S1040842820301165"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102978","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102978","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102978"}}